

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Friddle et al.

Application No.: 10/054,680

Filed: 01/22/02

Title: Novel Human Ion Exchanger Proteins and

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0301-USA

JAN 2 4 2003 TECH CENTER 1600/2900 Group Art Unit: 164

Examiner: To Be Assigned

Commissioner for Patents Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

<u>X</u>	under 37 CFR 1.97(b), or
	(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
	under 37 CFR 1.97(c) together with either a:  Certification under 37 CFR 1.97(e), or  a \$180.00 fee under 37 CFR 1.17(p), or  (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
—	under 37 CFR 1.97(d) together with a:  Certification under 37 CFR 1.97(e), and  a petition under 37 CFR 1.97(d)(2)(ii), and  a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).  (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Supplemental Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

January 16, 2003

Date

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

(281) 863-3333

2/231

PATENT TRADEMARK OFFICE